Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7363)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2023 (publication date) through Jun 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mandlik DS, Mandlik SK, Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2023; 29(6): 1054-1075 [PMID: 36844141 DOI: 10.3748/wjg.v29.i6.1054] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v29/i6/1054.htm |
| Number | Citing Articles |
| 1 |
Céleste Plantureux, Juliette Paillet, Gwennhael Autret, Maria Pérez-Lanzón, Guido Kroemer, Maria Chiara Maiuri, Jonathan Pol. Liver Carcinogenesis. Methods in Molecular Biology 2024; 2769: 99 doi: 10.1007/978-1-0716-3694-7_8
|
| 2 |
Tasneem Abaza, Mostafa K. Abd El-Aziz, Kerolos Ashraf Daniel, Paraskevi Karousi, Maria Papatsirou, Sherif Ashraf Fahmy, Nadia M. Hamdy, Christos K. Kontos, Rana A. Youness. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy. International Journal of Molecular Sciences 2023; 24(22): 16484 doi: 10.3390/ijms242216484
|
| 3 |
Keisuke Sawada, Hak Chung, Samir Softic, Maria E. Moreno-Fernandez, Senad Divanovic. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metabolism 2023; 35(11): 1852 doi: 10.1016/j.cmet.2023.10.009
|
| 4 |
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini. Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. Liver Cancer 2024; : 1 doi: 10.1159/000537915
|
| 5 |
Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments at the year-end of 2023. World Journal of Gastroenterology 2024; 30(1): 1-8 doi: 10.3748/wjg.v30.i1.1
Abstract(233) |
Core Tip(213) |
Full Article(HTML)(2588)
|
Full Article with Cover (PDF)-1825K(131)
|
Full Article (Word)-130K(25)
|
Audio-14227K(11)
|
Peer-Review Report-222K(33)
|
Answering Reviewers-194K(23)
|
Full Article (PDF)-407K(132)
|
Full Article (XML)-119K(36)
|
Times Cited (0)
|
Total Visits (7850)
|
Open
|
| 6 |
Yuri I. Buziashvili, Elmira U. Asymbekova, Elvina F. Tugeeva, Elena V. Artamonova, Firdavsdzhon R. Akildzhonov. Cardiotoxicity of checkpoint inhibitors: focus on immune side effects. Heart, Vessels and Transplantation 2024; 0(Ahead of Print) doi: 10.24969/hvt.2024.480
|
| 7 |
Diguang Wen, Shuling Wang, Jiajian Yu, Ting Yu, Zuojin Liu, Yue Li. Analysis of clinical significance and molecular characteristics of methionine metabolism and macrophage-related patterns in hepatocellular carcinoma based on machine learning. Cancer Biomarkers 2024; 39(1): 37 doi: 10.3233/CBM-220421
|
| 8 |
Shamar Young, Jack Hannallah, Dan Goldberg, Mohammad Khreiss, Rachna Shroff, Junaid Arshad, Aaron Scott, Gregory Woodhead. Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions. Seminars in Interventional Radiology 2023; 40(06): 515 doi: 10.1055/s-0043-1777711
|
| 9 |
Qiuyu Zhuang, Zhiguo Dai, Xuechun Xu, Shaoyi Bai, Yindan Zhang, Youshi Zheng, Xiaohua Xing, En Hu, Yingchao Wang, Wuhua Guo, Bixing Zhao, Yongyi Zeng, Xiaolong Liu. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion. Cancer Research 2024; 84(3): 405 doi: 10.1158/0008-5472.CAN-23-2049
|
| 10 |
Nguyen Pham, Jihane N. Benhammou. Statins in Chronic Liver Disease: Review of the Literature and Future Role. Seminars in Liver Disease 2024; doi: 10.1055/a-2319-0694
|
| 11 |
Shamar Young, Jack Hannallah, Dan Goldberg, Tina Sanghvi, Junaid Arshad, Aaron Scott, Gregory Woodhead. Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape. International Journal of Molecular Sciences 2023; 24(14): 11434 doi: 10.3390/ijms241411434
|
| 12 |
Nicolò Brandi, Matteo Renzulli. The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences 2023; 24(10): 8598 doi: 10.3390/ijms24108598
|
| 13 |
Yenisetti Rajendra Prasad, J. Anakha, Abhay H. Pande. Treating liver cancer through arginine depletion. Drug Discovery Today 2024; 29(4): 103940 doi: 10.1016/j.drudis.2024.103940
|
| 14 |
Xia-Qing Zhou, Ya-Ping Li, Shuang-Suo Dang. Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy. World Journal of Hepatology 2024; 16(2): 164-176 doi: 10.4254/wjh.v16.i2.164
Abstract(125) |
Core Tip(139) |
Full Article(HTML)(854)
|
Full Article with Cover (PDF)-2457K(36)
|
Full Article (Word)-656K(6)
|
Audio-417K(2)
|
Peer-Review Report-226K(17)
|
Answering Reviewers-105K(16)
|
Full Article (PDF)-1948K(25)
|
Full Article (XML)-211K(13)
|
Times Cited (1)
|
Total Visits (2090)
|
Open
|
| 15 |
Ju. I. Buziashvili, E. U. Asymbekova, E. F. Tugeeva, E. V. Artamonova, F. R. Akildzhonov. Cardiotoxicity of checkpoint inhibitors: focus on immune side effects. Medical alphabet 2024; (7): 26 doi: 10.33667/2078-5631-2024-7-26-33
|
| 16 |
Yacob Saleh, Taher Abu Hejleh, Maen Abdelrahim, Ali Shamseddine, Laudy Chehade, Tala Alawabdeh, Issa Mohamad, Mohammad Sammour, Rim Turfa. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Cancers 2024; 16(11): 2081 doi: 10.3390/cancers16112081
|
| 17 |
Zeynep Akbulut, Başak Aru, Furkan Aydın, Gülderen Yanıkkaya Demirel. Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1379622
|
| 18 |
Kashif Asghar, Shaarif Bashir, Muhammad Hassan, Asim Farooq, Muhammad Abu Bakar, Sundus Bilal, Maryam Hameed, Shafqat Mehmood, Asif Loya. Expression of PD-L1 clones (22C3 and 28-8) in hepatocellular carcinoma: a tertiary cancer care hospital experience. Egyptian Liver Journal 2024; 14(1) doi: 10.1186/s43066-024-00310-1
|
| 19 |
Margherita Rimini, Lorenzo Fornaro, Sara Lonardi, Monica Niger, Daniele Lavacchi, Tiziana Pressiani, Jessica Lucchetti, Guido Giordano, Andrea Pretta, Emiliano Tamburini, Chiara Pirrone, Ilario Giovanni Rapposelli, Anna Diana, Erika Martinelli, Ingrid Garajová, Francesca Simionato, Marta Schirripa, Vincenzo Formica, Caterina Vivaldi, Enrico Caliman, Mario Domenico Rizzato, Valentina Zanuso, Federico Nichetti, Lorenzo Angotti, Matteo Landriscina, Mario Scartozzi, Matteo Ramundo, Alessandro Pastorino, Bruno Daniele, Noemi Cornara, Mara Persano, Eleonora Gusmaroli, Riccardo Cerantola, Francesca Salani, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Lorenza Rimassa, Lorenzo Antonuzzo, Andrea Casadei‐Gardini. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data. Liver International 2023; 43(8): 1803 doi: 10.1111/liv.15641
|
| 20 |
Thomas M. Ruli, Ethan D. Pollack, Atul Lodh, Charles D. Evers, Christopher A. Price, Mohamed Shoreibah. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review. Cancers 2024; 16(11): 2042 doi: 10.3390/cancers16112042
|
| 21 |
JunJun Jia, Xuelian Zhou, Qingfei Chu. Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer. Molecular and Cellular Biochemistry 2024; doi: 10.1007/s11010-024-04983-5
|
| 22 |
Chaowen Zheng, Peng Dai, Hui You, Zhaokun Xian, Wenyun Su, Shixiong Wu, Dong Xing, Cuimin Sun. A compact microfluidic laser-induced fluorescence immunoassay system using avalanche photodiode for rapid detection of alpha-fetoprotein. Analytical Sciences 2024; doi: 10.1007/s44211-024-00553-3
|
| 23 |
Liman Qiu, Hongbing Ji, Kai Wang, Wenhan Liu, Qizhen Huang, Xinting Pan, Honghao Ye, Zhenli Li, Geng Chen, Xiaohua Xing, Xiuqing Dong, Ruijing Tang, Haipo Xu, Jingfeng Liu, Zhixiong Cai, Xiaolong Liu. TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. EMBO Molecular Medicine 2024; 16(5): 1193 doi: 10.1038/s44321-024-00068-4
|
| 24 |
Vincent Chin-Hung Chen, Shao-Lan Huang, Jing-Yu Huang, Tsai-Ching Hsu, Bor-Show Tzang, Roger S. McIntyre. Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis. International Journal of Molecular Sciences 2023; 24(16): 12630 doi: 10.3390/ijms241612630
|
| 25 |
Jian-Hong Zhong. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era. World Journal of Gastroenterology 2024; 30(8): 806-810 doi: 10.3748/wjg.v30.i8.806
Abstract(190) |
Core Tip(166) |
Full Article(HTML)(1017)
|
Full Article with Cover (PDF)-818K(90)
|
Full Article (Word)-224K(10)
|
Audio-482K(0)
|
Peer-Review Report-171K(23)
|
Answering Reviewers-10K(23)
|
Full Article (PDF)-451K(78)
|
Full Article (XML)-71K(46)
|
Times Cited (0)
|
Total Visits (2120)
|
Open
|
| 26 |
Litao Huang, Deying Kang, Chongyang Zhao, Xueting Liu. Correlation between surrogate endpoints and overall survival in unresectable hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54945-6
|
| 27 |
Ludovico Abenavoli, Michele Montori, Gianluca Svegliati Baroni, Maria Eva Argenziano, Francesca Giorgi, Giuseppe Guido Maria Scarlata, Francesca Ponziani, Emidio Scarpellini. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors. Medicina 2023; 59(8): 1427 doi: 10.3390/medicina59081427
|